Maintenence rituximab following induction in autoimmune cytopenias
Summary About 50% of immune thrombocytopenia (ITP) patients respond to rituximab induction, but most relapse. The effectiveness of rituximab maintenance remains untested. This study included autoimmune cytopenia patients who had previously responded to rituximab induction but subsequently relapsed....
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2023-07, Vol.202 (1), p.153-158 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 158 |
|---|---|
| container_issue | 1 |
| container_start_page | 153 |
| container_title | British journal of haematology |
| container_volume | 202 |
| creator | Rai, Manoj P. Lee, Eun‐Ju Bussel, James B. |
| description | Summary
About 50% of immune thrombocytopenia (ITP) patients respond to rituximab induction, but most relapse. The effectiveness of rituximab maintenance remains untested. This study included autoimmune cytopenia patients who had previously responded to rituximab induction but subsequently relapsed. After re‐induction, patients received rituximab maintenance regimen consisting of a single 375 mg/m2 dose administered at 4 month intervals, with a maximum of 6 doses. Primary endpoints were duration of response and safety. Sixteen patients: ITP (9), autoimmune haemolytic anaemia (2), and Evans syndrome (5) received rituximab maintenance. 15/16 achieved complete response (CR); 8/15 CR + 1 partial reponse remain in remission. Median response: 43 months; estimated 5‐year relapse‐free >50%. Three developed hypogammaglobulinemia. Rituximab maintenance led to prolonged remissions in patients with autoimmune cytopenias who had previously responded to rituximab induction. |
| doi_str_mv | 10.1111/bjh.18814 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2805028822</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2829301767</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-e1283fe2d8ac55afd14c154d34b97e1331ebdf7352e1f6aad754d9ccb7f7ba073</originalsourceid><addsrcrecordid>eNp1kMFOwzAMhiMEYmNw4AVQJS5w6BYn7ZId2QQMNMQFzlWaupCpTUbTauztydjggIQvtuRPn-yfkHOgQwg1ypfvQ5ASkgPSBz5OYwYJHJI-pVTEQBPZIyfeLykFTlM4Jj0uqByD4H0yfVLGtmjRaowa03afplZ5VLqqcmtj3yJji063xtkwRaprnanrzmKkN61boTXKn5KjUlUez_Z9QF7vbl9m83jxfP8wu1nEmqc8iRGY5CWyQiqdpqosINGQJgVP8olA4BwwL0rBU4ZQjpUqRFhOtM5FKXJFBR-Qq5131biPDn2b1cZrrCpl0XU-Y5KmlEnJWEAv_6BL1zU2XBcoNuEUxHgrvN5RunHeN1hmqyZ832wyoNk22CwEm30HG9iLvbHLayx-yZ8kAzDaAWtT4eZ_UzZ9nO-UXwikgiY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2829301767</pqid></control><display><type>article</type><title>Maintenence rituximab following induction in autoimmune cytopenias</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Wiley Online Library Free Content</source><creator>Rai, Manoj P. ; Lee, Eun‐Ju ; Bussel, James B.</creator><creatorcontrib>Rai, Manoj P. ; Lee, Eun‐Ju ; Bussel, James B.</creatorcontrib><description>Summary
About 50% of immune thrombocytopenia (ITP) patients respond to rituximab induction, but most relapse. The effectiveness of rituximab maintenance remains untested. This study included autoimmune cytopenia patients who had previously responded to rituximab induction but subsequently relapsed. After re‐induction, patients received rituximab maintenance regimen consisting of a single 375 mg/m2 dose administered at 4 month intervals, with a maximum of 6 doses. Primary endpoints were duration of response and safety. Sixteen patients: ITP (9), autoimmune haemolytic anaemia (2), and Evans syndrome (5) received rituximab maintenance. 15/16 achieved complete response (CR); 8/15 CR + 1 partial reponse remain in remission. Median response: 43 months; estimated 5‐year relapse‐free >50%. Three developed hypogammaglobulinemia. Rituximab maintenance led to prolonged remissions in patients with autoimmune cytopenias who had previously responded to rituximab induction.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18814</identifier><identifier>PMID: 37086173</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Anemia, Hemolytic, Autoimmune - drug therapy ; anti‐CD20 ; autoimmune haemolytic anaemia (AIHA) ; Autoimmune hemolytic anemia ; Cytopenia ; Evans syndrome (ES) ; Hematology ; Hemolytic anemia ; Humans ; Hypogammaglobulinemia ; Idiopathic thrombocytopenic purpura ; immune thrombocytopenia (ITP) ; outcomes ; Purpura, Thrombocytopenic, Idiopathic - drug therapy ; Recurrence ; Remission ; Remission Induction ; Retrospective Studies ; Rituximab ; Rituximab - adverse effects ; Thrombocytopenia - chemically induced ; Thrombocytopenia - drug therapy ; Treatment Outcome</subject><ispartof>British journal of haematology, 2023-07, Vol.202 (1), p.153-158</ispartof><rights>2023 British Society for Haematology and John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-e1283fe2d8ac55afd14c154d34b97e1331ebdf7352e1f6aad754d9ccb7f7ba073</citedby><cites>FETCH-LOGICAL-c3534-e1283fe2d8ac55afd14c154d34b97e1331ebdf7352e1f6aad754d9ccb7f7ba073</cites><orcidid>0000-0003-4162-033X ; 0000-0002-2884-9247 ; 0000-0002-8340-6027</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.18814$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.18814$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27922,27923,45572,45573,46407,46831</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37086173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rai, Manoj P.</creatorcontrib><creatorcontrib>Lee, Eun‐Ju</creatorcontrib><creatorcontrib>Bussel, James B.</creatorcontrib><title>Maintenence rituximab following induction in autoimmune cytopenias</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
About 50% of immune thrombocytopenia (ITP) patients respond to rituximab induction, but most relapse. The effectiveness of rituximab maintenance remains untested. This study included autoimmune cytopenia patients who had previously responded to rituximab induction but subsequently relapsed. After re‐induction, patients received rituximab maintenance regimen consisting of a single 375 mg/m2 dose administered at 4 month intervals, with a maximum of 6 doses. Primary endpoints were duration of response and safety. Sixteen patients: ITP (9), autoimmune haemolytic anaemia (2), and Evans syndrome (5) received rituximab maintenance. 15/16 achieved complete response (CR); 8/15 CR + 1 partial reponse remain in remission. Median response: 43 months; estimated 5‐year relapse‐free >50%. Three developed hypogammaglobulinemia. Rituximab maintenance led to prolonged remissions in patients with autoimmune cytopenias who had previously responded to rituximab induction.</description><subject>Anemia, Hemolytic, Autoimmune - drug therapy</subject><subject>anti‐CD20</subject><subject>autoimmune haemolytic anaemia (AIHA)</subject><subject>Autoimmune hemolytic anemia</subject><subject>Cytopenia</subject><subject>Evans syndrome (ES)</subject><subject>Hematology</subject><subject>Hemolytic anemia</subject><subject>Humans</subject><subject>Hypogammaglobulinemia</subject><subject>Idiopathic thrombocytopenic purpura</subject><subject>immune thrombocytopenia (ITP)</subject><subject>outcomes</subject><subject>Purpura, Thrombocytopenic, Idiopathic - drug therapy</subject><subject>Recurrence</subject><subject>Remission</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Rituximab - adverse effects</subject><subject>Thrombocytopenia - chemically induced</subject><subject>Thrombocytopenia - drug therapy</subject><subject>Treatment Outcome</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMFOwzAMhiMEYmNw4AVQJS5w6BYn7ZId2QQMNMQFzlWaupCpTUbTauztydjggIQvtuRPn-yfkHOgQwg1ypfvQ5ASkgPSBz5OYwYJHJI-pVTEQBPZIyfeLykFTlM4Jj0uqByD4H0yfVLGtmjRaowa03afplZ5VLqqcmtj3yJji063xtkwRaprnanrzmKkN61boTXKn5KjUlUez_Z9QF7vbl9m83jxfP8wu1nEmqc8iRGY5CWyQiqdpqosINGQJgVP8olA4BwwL0rBU4ZQjpUqRFhOtM5FKXJFBR-Qq5131biPDn2b1cZrrCpl0XU-Y5KmlEnJWEAv_6BL1zU2XBcoNuEUxHgrvN5RunHeN1hmqyZ832wyoNk22CwEm30HG9iLvbHLayx-yZ8kAzDaAWtT4eZ_UzZ9nO-UXwikgiY</recordid><startdate>202307</startdate><enddate>202307</enddate><creator>Rai, Manoj P.</creator><creator>Lee, Eun‐Ju</creator><creator>Bussel, James B.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4162-033X</orcidid><orcidid>https://orcid.org/0000-0002-2884-9247</orcidid><orcidid>https://orcid.org/0000-0002-8340-6027</orcidid></search><sort><creationdate>202307</creationdate><title>Maintenence rituximab following induction in autoimmune cytopenias</title><author>Rai, Manoj P. ; Lee, Eun‐Ju ; Bussel, James B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-e1283fe2d8ac55afd14c154d34b97e1331ebdf7352e1f6aad754d9ccb7f7ba073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anemia, Hemolytic, Autoimmune - drug therapy</topic><topic>anti‐CD20</topic><topic>autoimmune haemolytic anaemia (AIHA)</topic><topic>Autoimmune hemolytic anemia</topic><topic>Cytopenia</topic><topic>Evans syndrome (ES)</topic><topic>Hematology</topic><topic>Hemolytic anemia</topic><topic>Humans</topic><topic>Hypogammaglobulinemia</topic><topic>Idiopathic thrombocytopenic purpura</topic><topic>immune thrombocytopenia (ITP)</topic><topic>outcomes</topic><topic>Purpura, Thrombocytopenic, Idiopathic - drug therapy</topic><topic>Recurrence</topic><topic>Remission</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Rituximab - adverse effects</topic><topic>Thrombocytopenia - chemically induced</topic><topic>Thrombocytopenia - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rai, Manoj P.</creatorcontrib><creatorcontrib>Lee, Eun‐Ju</creatorcontrib><creatorcontrib>Bussel, James B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rai, Manoj P.</au><au>Lee, Eun‐Ju</au><au>Bussel, James B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maintenence rituximab following induction in autoimmune cytopenias</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2023-07</date><risdate>2023</risdate><volume>202</volume><issue>1</issue><spage>153</spage><epage>158</epage><pages>153-158</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
About 50% of immune thrombocytopenia (ITP) patients respond to rituximab induction, but most relapse. The effectiveness of rituximab maintenance remains untested. This study included autoimmune cytopenia patients who had previously responded to rituximab induction but subsequently relapsed. After re‐induction, patients received rituximab maintenance regimen consisting of a single 375 mg/m2 dose administered at 4 month intervals, with a maximum of 6 doses. Primary endpoints were duration of response and safety. Sixteen patients: ITP (9), autoimmune haemolytic anaemia (2), and Evans syndrome (5) received rituximab maintenance. 15/16 achieved complete response (CR); 8/15 CR + 1 partial reponse remain in remission. Median response: 43 months; estimated 5‐year relapse‐free >50%. Three developed hypogammaglobulinemia. Rituximab maintenance led to prolonged remissions in patients with autoimmune cytopenias who had previously responded to rituximab induction.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>37086173</pmid><doi>10.1111/bjh.18814</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4162-033X</orcidid><orcidid>https://orcid.org/0000-0002-2884-9247</orcidid><orcidid>https://orcid.org/0000-0002-8340-6027</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2023-07, Vol.202 (1), p.153-158 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2805028822 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; Wiley Online Library Free Content |
| subjects | Anemia, Hemolytic, Autoimmune - drug therapy anti‐CD20 autoimmune haemolytic anaemia (AIHA) Autoimmune hemolytic anemia Cytopenia Evans syndrome (ES) Hematology Hemolytic anemia Humans Hypogammaglobulinemia Idiopathic thrombocytopenic purpura immune thrombocytopenia (ITP) outcomes Purpura, Thrombocytopenic, Idiopathic - drug therapy Recurrence Remission Remission Induction Retrospective Studies Rituximab Rituximab - adverse effects Thrombocytopenia - chemically induced Thrombocytopenia - drug therapy Treatment Outcome |
| title | Maintenence rituximab following induction in autoimmune cytopenias |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T07%3A23%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maintenence%20rituximab%20following%20induction%20in%20autoimmune%20cytopenias&rft.jtitle=British%20journal%20of%20haematology&rft.au=Rai,%20Manoj%20P.&rft.date=2023-07&rft.volume=202&rft.issue=1&rft.spage=153&rft.epage=158&rft.pages=153-158&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18814&rft_dat=%3Cproquest_cross%3E2829301767%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2829301767&rft_id=info:pmid/37086173&rfr_iscdi=true |